Monopar Therapeutics Files 8-K

Ticker: MNPR · Form: 8-K · Filed: 2024-06-10T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 8-K

TL;DR

Monopar filed an 8-K, standard procedure, no major news yet.

AI Summary

On June 10, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events, financial figures, or new developments were detailed in the provided excerpt.

Why It Matters

This filing indicates Monopar Therapeutics is complying with regulatory requirements for reporting material information and financial updates to the public.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases or decreases risk.

Key Players & Entities

Monopar Therapeutics Inc. (company) — Registrant
June 10, 2024 (date) — Date of earliest event reported
Delaware (jurisdiction) — State of incorporation
001-39070 (identifier) — Commission File Number
32-0463781 (identifier) — I.R.S. Employer Identification No.
1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Address of principal executive offices
847-388-0349 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing by Monopar Therapeutics?

The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.

When was the earliest event reported in this filing?

The earliest event reported is dated June 10, 2024.

In which state is Monopar Therapeutics incorporated?

Monopar Therapeutics Inc. is incorporated in Delaware.

What is the principal executive office address for Monopar Therapeutics?

The principal executive offices are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

Does this filing excerpt detail any specific new business developments or financial results?

No, the provided excerpt of the 8-K filing does not detail specific new business developments or financial results; it focuses on the filing's nature and the company's basic information.

From the Filing

0001437749-24-019747.txt : 20240610 0001437749-24-019747.hdr.sgml : 20240610 20240610080017 ACCESSION NUMBER: 0001437749-24-019747 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240610 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241031500 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240608c_8k.htm FORM 8-K mnpr20240608c_8k.htm false 0001645469 0001645469 2024-06-10 2024-06-10     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934     Date of Report (Date of earliest event reported):    June 10, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock , $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On June 10, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing a poster presentation summarizing data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada.   The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press R